⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 21, 2024Artificial OrgansOpen Access

Cytokine adsorption in patients with acute‐on‐chronic liver failure (CYTOHEP)—A single center, open‐label, three‐arm, randomized, controlled intervention pilot trial

Asieb Sekandarzad Erika Graf Eric Peter Prager Hendrik Luxenburger Dawid L. Staudacher Tobias Wengenmayer Dominik Bettinger Alexander Supady

View Full Paper

Ask AI

Bookmark

Share

Abstract

To investigate the efficacy of bilirubin reduction by hemoadsorption with CytoSorb® in patients with acute-on-chronic liver failure (ACLF) receiving continuous renal replacement therapy (CRRT).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sekandarzad et al. (2024) studied this question.

synapsesocial.com/papers/68e69105b6db643587617e16 https://doi.org/10.1111/aor.14774

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Use of the CytoSorb adsorber in patients with acute-on-chronic liver failure2024 · 29 citations
2Feasibility and Safety of Cytosorb Application in Patients With Acute Liver FailureRetrospective Study · 2025 · 2 citations
3Artificial liver support with Cytosorb and continuous veno-venous hemodiafiltration versus advanced organ support (ADVOS) for critically ill patients with hyperbilirubinemia and acute-on-chronic liver failure (ACLF)2025 · 3 citations
4Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International RegistryCase Report · 2021 · 35 citations
5Blood Purification in Hepatic Dysfunction after Liver Transplant or Extensive Hepatectomy: Far from the Best-Case Scenarios2024 · 4 citations